SiO2 Medical Products, Inc. (SMP) is a U.S. based, privately-held company founded in 2011. SMP has successfully developed and commercialized a wide range of novel products for use in pharmaceutical ...

SiO2 Medical Products announced a strategic investment by Novartis to explore and potentially use its materials sciences for packaging technology in a range of products. Investment confirms interest ...

Investment confirms interest to use SiO2's technology that may provide advantages including enhanced quality and performance SiO2's breakthrough technology is anticipated to help provide regulatory ...

AUBURN, Ala., Aug. 1, 2017 /PRNewswire/ -- SiO 2 Medical Products, Inc. ("SMP"), a U.S.-based designer, developer, manufacturer, and supplier of pharmaceutical ...

SiO2 Medical Products today announced a strategic investment by Novartis to explore and potentially use its materials sciences for packaging technology in a range of products. SiO2's containers are ...

Enhanced packaging (low particulates, Silicone oil and Tungsten-free, no delamination, glass-like oxygen barrier, tighter dimensional control, no breakage); Innovative materials science technology to ...

AUBURN, Alabama, Nov. 18, 2019 /PRNewswire/ -- SiO2 Medical Products today announced a strategic investment by Novartis to explore and potentially use its materials sciences for packaging technology ...

Novartis is based in Basel, Switzerland. Credit: Wiki Commons / Andrew. Swiss pharmaceutical company Novartis has made a strategic investment in US-based biotech industries packaging company SiO2 ...

Pharmaceutical and biological customers can benefit from an extended supplier offering for their fill-finish lines and from a faster drug product time-to-market PADUA, Italy and AUBURN, Alabama, Feb.

Investment confirms interest to use SiO2's technology that may provide advantages including enhanced quality and performance AUBURN, Alabama, Nov. 18, 2019 /PRNewswire/ -- SiO2 Medical Products today ...

Pharmaceutical and biological customers can benefit from an extended supplier offering for their fill-finish lines and from a faster drug product time-to-market The agreement will enable ...